Svenja Happe

4.4k total citations
94 papers, 2.9k citations indexed

About

Svenja Happe is a scholar working on Epidemiology, Neurology and Cognitive Neuroscience. According to data from OpenAlex, Svenja Happe has authored 94 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 61 papers in Epidemiology, 53 papers in Neurology and 51 papers in Cognitive Neuroscience. Recurrent topics in Svenja Happe's work include Restless Legs Syndrome Research (55 papers), Parkinson's Disease Mechanisms and Treatments (48 papers) and Sleep and Wakefulness Research (47 papers). Svenja Happe is often cited by papers focused on Restless Legs Syndrome Research (55 papers), Parkinson's Disease Mechanisms and Treatments (48 papers) and Sleep and Wakefulness Research (47 papers). Svenja Happe collaborates with scholars based in Germany, Austria and United States. Svenja Happe's co-authors include J. Zeitlhofer, Walter Paulus, Klaus Berger, Claudia Trenkwalder, Gerhard Klösch, Michael A. Nitsche, B. Saletu, Stefan Evers, Cornelius G. Bachmann and Peter Young and has published in prestigious journals such as SHILAP Revista de lepidopterología, Brain and Neurology.

In The Last Decade

Svenja Happe

92 papers receiving 2.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Svenja Happe Germany 35 1.5k 1.5k 1.4k 641 396 94 2.9k
Louis De Beaumont Canada 24 733 0.5× 629 0.4× 1.1k 0.8× 282 0.4× 407 1.0× 88 2.3k
Magdolna Hornyak Germany 35 2.4k 1.5× 1.2k 0.8× 1.6k 1.1× 1.6k 2.5× 108 0.3× 87 3.6k
M Rousseaux France 37 1.7k 1.1× 914 0.6× 646 0.4× 205 0.3× 324 0.8× 198 4.2k
Rita Formisano Italy 31 630 0.4× 1.5k 1.0× 2.2k 1.5× 138 0.2× 241 0.6× 184 3.8k
Claus‐W. Wallesch Germany 31 1.1k 0.7× 771 0.5× 673 0.5× 162 0.3× 304 0.8× 101 2.7k
Kaisa M. Hartikainen Finland 24 774 0.5× 478 0.3× 542 0.4× 158 0.2× 193 0.5× 49 1.7k
José León‐Carrión Spain 26 883 0.6× 856 0.6× 1.3k 0.9× 183 0.3× 145 0.4× 63 2.9k
S E Starkstein United States 20 1.2k 0.8× 1.5k 1.0× 534 0.4× 217 0.3× 388 1.0× 26 3.5k
Zeev Groswasser Israel 29 437 0.3× 1.1k 0.8× 1.3k 0.9× 117 0.2× 188 0.5× 83 2.4k
G. Saletu‐Zyhlarz Austria 28 1.6k 1.0× 754 0.5× 914 0.6× 663 1.0× 53 0.1× 75 2.3k

Countries citing papers authored by Svenja Happe

Since Specialization
Citations

This map shows the geographic impact of Svenja Happe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Svenja Happe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Svenja Happe more than expected).

Fields of papers citing papers by Svenja Happe

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Svenja Happe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Svenja Happe. The network helps show where Svenja Happe may publish in the future.

Co-authorship network of co-authors of Svenja Happe

This figure shows the co-authorship network connecting the top 25 collaborators of Svenja Happe. A scholar is included among the top collaborators of Svenja Happe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Svenja Happe. Svenja Happe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rose, Olaf, et al.. (2021). Enhancing medication therapy in Parkinson's disease by establishing an interprofessional network including pharmacists. International Journal of Clinical Pharmacy. 43(3). 441–448. 4 indexed citations
2.
3.
Lang, Nicolas, Stefan Evers, Christoph Kellinghaus, et al.. (2015). Intravenous levetiracetam in clinical practice – Results from an independent registry. Seizure. 29. 109–113. 6 indexed citations
4.
Pollmächer, Thomas, Thomas C. Wetter, Svenja Happe, et al.. (2013). Schlafmedizinische Differenzialdiagnostik in Psychiatrie und Psychotherapie. Der Nervenarzt. 85(1). 57–66. 4 indexed citations
5.
Hornyak, Magdolna, K. Stiasny-Kolster, Stefan Evers, & Svenja Happe. (2011). Restless-Legs-Syndrom und nächtliche Beinschmerzen: Differenzialdiagnose und Therapie. Der Schmerz. 25(5). 544–551. 1 indexed citations
6.
Högl, Birgit, Diego García‐Borreguero, Ralf Kohnen, et al.. (2009). Progressive development of augmentation during long-term treatment with levodopa in restless legs syndrome: results of a prospective multi-center study. Journal of Neurology. 257(2). 230–237. 68 indexed citations
7.
Happe, Svenja, Jens Peter Reese, Karin Stiasny‐Kolster, et al.. (2008). Assessing health-related quality of life in patients with restless legs syndrome. Sleep Medicine. 10(3). 295–305. 101 indexed citations
8.
García‐Borreguero, Diego, Ralf Kohnen, Birgit Högl, et al.. (2007). Validation of the Augmentation Severity Rating Scale (ASRS): A multicentric, prospective study with levodopa on restless legs syndrome. Sleep Medicine. 8(5). 455–463. 76 indexed citations
9.
Hildebrandt, Helmut, et al.. (2007). Brain perfusion and VEP reactivity in occipital and parietal areas are associated to recovery from hypoxic vegetative state. Journal of the Neurological Sciences. 260(1-2). 150–158. 20 indexed citations
10.
Happe, Svenja, et al.. (2007). Association of daytime sleepiness with nigrostriatal dopaminergic degeneration in early Parkinson's disease. Journal of Neurology. 254(8). 1037–1043. 70 indexed citations
11.
García‐Borreguero, Diego, Richard P. Allen, Heike Beneš, et al.. (2007). Augmentation as a treatment complication of restless legs syndrome: Concept and management. Movement Disorders. 22(S18). S476–S484. 67 indexed citations
12.
Happe, Svenja, Cornelius G. Bachmann, Karin Neubert, et al.. (2007). Growth hormone response to low-dose apomorphine in restless legs syndrome. Growth Hormone & IGF Research. 17(4). 323–327. 4 indexed citations
13.
Steinig, Jana, Gerhard Klösch, Cornelia Sauter, J. Zeitlhofer, & Svenja Happe. (2007). Actigraphy in irregular sleep–wake rhythm. Sleep Medicine. 8(2). 184–185. 2 indexed citations
14.
Happe, Svenja, et al.. (2005). Restless Legs Syndrome and Sleep Problems in Children and Adolescents with Insulin-Dependent Diabetes Mellitus Type 1. Neuropediatrics. 36(2). 98–103. 34 indexed citations
15.
Happe, Svenja, Tobias Tings, Karin Neubert, et al.. (2004). Levodopa treatment does not affect low‐dose apomorphine test in patients with Parkinson's disease. Movement Disorders. 19(12). 1511–1515. 7 indexed citations
16.
Happe, Svenja. (2002). The association between caregiver burden and sleep disturbances in partners of patients with Parkinson's disease. Age and Ageing. 31(5). 349–354. 105 indexed citations
17.
Happe, Svenja & Klaus Berger. (2001). The association of dopamine agonists with daytime sleepiness, sleep problems and quality of life in patients with Parkinson's disease. Journal of Neurology. 248(12). 1062–1067. 52 indexed citations
18.
Happe, Svenja, et al.. (2000). Persistence of rhythmic movement disorder beyond childhood: A videotape demonstration. Movement Disorders. 15(6). 1296–1298. 17 indexed citations
19.
Happe, Svenja, et al.. (2000). Progressive multifokale Leukoenzephalopathie im Verlauf der AIDS-Erkrankung. Der Nervenarzt. 71(2). 96–104. 6 indexed citations
20.
Happe, Svenja, et al.. (1999). Scleroedema adultorum Buschke als seltene Differnetialdiagnose des Stiff-man-Syndroms. Der Nervenarzt. 70(10). 916–919. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Louis De Beaumont Breakdown of academic impact, for papers by Magdolna Hornyak Breakdown of academic impact, for papers by M Rousseaux Breakdown of academic impact, for papers by Rita Formisano Breakdown of academic impact, for papers by Claus‐W. Wallesch Breakdown of academic impact, for papers by Kaisa M. Hartikainen Breakdown of academic impact, for papers by José León‐Carrión Breakdown of academic impact, for papers by S E Starkstein Breakdown of academic impact, for papers by Zeev Groswasser Breakdown of academic impact, for papers by G. Saletu‐Zyhlarz
Rankless by CCL
2026